Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years
FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.
Nasdaq15d
Tonix Pharmaceuticals Announces FDA PDUFA Goal Date for TNX-102 SL and Positive Developments Across Pipeline
Tonix Pharmaceuticals Holding Corp. announced that the FDA has set a PDUFA goal date of August 15, 2025, for TNX-102 SL, which, if approved, would be the first new drug for fibromyalgia in over 15 ...
PharmiWeb2d
Tonix’s Experimental Non-Opioid Analgesic Treatment for Fibromyalgia Could Start Bringing Relief Later This Year
CHATHAM, NJ / ACCESS Newswire / March 31, 2025 / This post was written and published as a collaboration between the in-house ...
Tonix says FDA will not require committee meeting for TNX-102 SL NDA
Tonix Pharmaceuticals (TNXP) announced that the U.S. Food and Drug Administration will not require an Advisory Committee meeting to discuss the ...
Business Insider29d
Tonix Pharmaceuticals presents new data on TNX-102 SL treatment
Tonix Pharmaceuticals (TNXP) presented data in an oral presentation at the 7th International Congress on Controversies in Fibromyalgia, held March 3-4, 2025, in Vienna, Austria. TNX-102 SL is a ...
Tonix Pharmaceuticals Shares Jump After FDA Guidance for TNX-102
The FDA previously granted Fast Track designation to TNX-102 SL for the management of fibromyalgia in 2024, a designation intended to expedite FDA review of important new drugs to treat serious ...
MarketBeat on MSN8d
Pharma Frenzy: Volatility Ignites Biotech Sector
The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price ...
American Association of Individual Investors2d
Why Tonix Pharmaceuticals Holding Corp.’s (TNXP) Stock Is Down 11.27%
Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 11.27%, which has investors questioning if this is right time to buy.
Why Tonix Pharmaceuticals (TNXP) Stock Is Rising
Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...
What's Going On With Tonix Pharmaceuticals (TNXP) Stock?
Shares of Tonix Pharmaceuticals are pulling back 12.7% during Thursday's session. The stock is pulling back following a regulatory update on its experimental fibromyalgia treatment, TNX-102 SL.